If the original quarterly numbers Generex put in an SEC filing are deemed unreliable by the company, because Veneto inputted inter-company transactions, did that also deem the amendment filed in December by Generex as being unreliable? Those lofty revenue numbers- inter-company? Was that for all of “Medoc Health” or just the part that Generex was acquiring? The answers probably make sense, I’m just pointing out to Gnbt simple curiosities investors would have.